Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SkinBioTherapeutics ( (GB:SBTX) ) just unveiled an announcement.
SkinBioTherapeutics has announced the first phase of its AxisBiotix™ launch in collaboration with Superdrug, a leading UK health and beauty retailer. The AxisBiotix™ food supplements, designed to alleviate inflammatory skin conditions, will initially be available in select Superdrug stores with high sales of medicated skincare, with a broader rollout planned for Spring 2026. This exclusive two-year agreement marks SkinBioTherapeutics’ first national high street partnership, representing a significant milestone for the company as it expands its market presence and product availability.
The most recent analyst rating on (GB:SBTX) stock is a Sell with a £16.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Underperform.
SkinBioTherapeutics faces significant financial challenges with ongoing losses and cash burn, which heavily influence its stock score. While technical indicators show bearish trends, recent positive corporate events and strategic moves offer potential future benefits. However, until these translate into improved financial performance, the stock’s score remains low.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life science company focused on skin health, utilizing its proprietary platform technology, SkinBiotix®, developed by the University of Manchester’s translational dermatology team. The company targets the skin healthcare market through five pillars, with a focus on cosmetic skincare and food supplements like AxisBiotix-Ps™, which addresses inflammatory skin conditions. The company is expanding through acquisitions and partnerships, including a collaboration with Croda plc, and is listed on AIM since April 2017, based in Newcastle, UK.
Average Trading Volume: 726,786
Technical Sentiment Signal: Sell
Current Market Cap: £38.49M
For detailed information about SBTX stock, go to TipRanks’ Stock Analysis page.